FDA Approves HIV-1 Treatment Idvynso on April 21

The FDA approved Idvynso (doravirine/islatravir combination) on April 21 for the treatment of adult HIV-1 infection. On April 23, the genetic hearing loss gene therapy Otarmeni (lunsotogene parvec-cwha) received accelerated approval. On April 22, Eli Lilly's Foundayo and Novo Nordisk's Wegovy pill entered competition in the GLP-1 oral market.